Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 25(3): 602-6, 2015 Feb 01.
Article in English | MEDLINE | ID: mdl-25556095

ABSTRACT

Small molecule (1) has been identified as a selective partial agonist of Opioid Receptor Like-1 (ORL-1) with potential utility for the treatment of anxiety and other disorders. Nociceptin (orphanin FQ) is an endogenous peptide ligand that binds to ORL-1, however it does not bind the classical δ, µ and κ opioid receptors with high affinity. The synthesis of 1 involved using a molecular diversity approach, to rapidly advance a library of compounds for biological testing. A lead selective potent partial agonist (35-fold ORL-1/Mu) progressed to ORL-1 (NOP or OP4) proof of concept testing in advanced studies. The synthetic approach and biological data for the related chemical series will be presented.


Subject(s)
Receptors, Opioid/agonists , Small Molecule Libraries/chemistry , Spiro Compounds/chemistry , Animals , Anxiety/drug therapy , Disease Models, Animal , Motor Activity/drug effects , Opioid Peptides/chemistry , Opioid Peptides/metabolism , Protein Binding , Rats , Receptors, Opioid/metabolism , Small Molecule Libraries/pharmacology , Small Molecule Libraries/therapeutic use , Spiro Compounds/pharmacology , Spiro Compounds/therapeutic use , Structure-Activity Relationship , Nociceptin Receptor , Nociceptin
2.
Alcohol Clin Exp Res ; 33(8): 1366-73, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19413647

ABSTRACT

BACKGROUND: Since 1994, when naltrexone (Revia) was approved by the FDA for the treatment of alcoholism, only 2 other drugs (Campral and Topamax have been approved for alcoholism treatment. However, various experimental drugs, including antiepileptic medications, have been tested in both animal models and in humans with some promising results. The purpose of this project was to study the effect of the novel neuromodulator carisbamate, which is in development for epilepsy treatment, on alcohol intake in selectively bred alcohol-preferring rats. METHODS: Male alcohol-preferring inbred P rats were allowed to freely drink water or alcohol (10%, v/v) using a 2-bottle choice procedure. After stable baselines for alcohol and water intakes were established, the acute effects of oral carisbamate (0, 10, 30, 45, 60, and 90 mg/kg) were assessed. Then, the chronic effect of the compound (60 mg/kg/day for 14 consecutive days) on alcohol intake was assessed in a separate group of male P rats. In another set of experiments, the effects of carisbamate and naltrexone on alcohol withdrawal-induced elevated drinking of alcohol, an index of craving, were compared. Rats were withdrawn from alcohol for 24 hours and were given vehicle, 20 mg/kg naltrexone or 60 mg/kg carisbamate 30 minutes before re-exposure to alcohol. Alcohol and water intake was measured 6 hours after alcohol re-exposure. To determine the effects of carisbamate on saccharin preference, rats were put on a 2-bottle choice of water versus a solution of 2% saccharin. Then, the effect of the highest dose of carisbamate (90 mg/kg) and naltrexone (20 mg/kg) and the vehicle on saccharin preference was determined. RESULTS: Our results showed that there was a selective dose-dependent reduction in alcohol intake and preference in the alcohol-preferring P rat after an acute oral administration of carisbamate. There were no significant effects on food or water intake. Chronic administration of carisbamate significantly reduced alcohol intake and preference initially, but partial tolerance developed after the 10th treatment. The degree of tolerance development was less than that observed for naltrexone. Acute administration of carisbamate was more effective than naltrexone in reducing enhanced alcohol intake after a period of alcohol deprivation. Compared with control vehicle neither carisbamate nor naltrexone had a significant effect on saccharin intake and preference. CONCLUSION: The novel neuromodulator compound carisbamate has a favorable profile of effects on alcohol intake and related measures and should be considered for testing on human alcoholics.


Subject(s)
Alcohol Drinking/genetics , Alcohol Drinking/prevention & control , Anticonvulsants/administration & dosage , Carbamates/administration & dosage , Disease Models, Animal , Administration, Oral , Animals , Anticonvulsants/chemistry , Carbamates/chemistry , Dose-Response Relationship, Drug , Male , Rats , Time Factors
3.
Alcohol Clin Exp Res ; 31(1): 57-63, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17207102

ABSTRACT

BACKGROUND: N-Phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) is a structurally novel atypical anxiolytic with an overall in vivo profile in animals suggestive of the potential to show anxiolytic efficacy in humans at doses that will not cause CNS-related side effects. Furthermore, unlike the benzodiazepines, JNJ-5234801 does not have an adverse interaction with ethanol even at doses 20 to 40 times the minimal effective dose in the rat elevated plus maze (MED=1.0 mg/kg, p.o.). METHODS: In the present study, JNJ-5234801 was evaluated for potential efficacy in reducing alcohol intake in alcohol-preferring rats. Alcohol-preferring P rats were allowed to drink water or alcohol (10%, v/v) in a 2-bottle choice procedure. Once stable baselines were established, the acute effects of JNJ-5234801 [(10-40 mg/kg, intraperitoneally (i.p.)] were assessed. In a separate study, chronic treatment with JNJ-5234801 (40 mg/kg once daily, i.p.) for 12 consecutive days was compared with naltrexone (20 mg/kg, twice daily, i.p.). RESULTS: There was a selective dose-dependent reduction in alcohol intake in the alcohol-preferring (P) rats after acute administration of JNJ-5234801 (10-40 mg/kg, i.p.). There were no significant effects on food or water intake. When administered subchronically, both JNJ-5234801 (40 mg/kg once daily, i.p.) and naltrexone (20 mg/kg, twice daily, i.p.) considerably reduced alcohol intake, but tolerance to the alcohol-suppressing effects appeared to occur sooner in the naltrexone-treated group. While both compounds slightly but significantly reduced food intake at the beginning, only JNJ-5234801 increased water intake and decreased alcohol preference. CONCLUSIONS: The novel atypical anxiolytic JNJ-5234801 has a favorable profile effects on alcohol intake and related measures compared with naltrexone, which is recommended for the treatment of alcoholism.


Subject(s)
Alcohol Drinking/drug therapy , Alcohol Drinking/genetics , Anti-Anxiety Agents/pharmacology , Piperidines/pharmacology , Pyridines/pharmacology , Acute Disease , Animals , Chronic Disease , Dose-Response Relationship, Drug , Drinking/drug effects , Drug Tolerance , Injections, Intraperitoneal , Male , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Rats
4.
Bioorg Med Chem Lett ; 16(11): 3065-7, 2006 Jun 01.
Article in English | MEDLINE | ID: mdl-16580201

ABSTRACT

N-Phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (9) and related piperidine acetamide derivatives have good oral activity in the elevated plus maze, an animal model predictive of clinical efficacy for the treatment of anxiety. Modest affinity was observed for the neurokinin NK-1 and 2 receptors, which are known to be involved in the regulation of mood and emotion.


Subject(s)
Acetylene/chemistry , Amides/chemistry , Amides/pharmacology , Anti-Anxiety Agents/chemical synthesis , Anti-Anxiety Agents/pharmacology , Amides/chemical synthesis , Animals , Anti-Anxiety Agents/chemistry , CHO Cells , Cricetinae , Humans , Mice , Molecular Structure , Structure-Activity Relationship
5.
J Biomol Screen ; 8(1): 65-71, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12854999

ABSTRACT

Target validation is one of rate-limiting steps in the modern drug discovery. The authors developed a strategy of combining adenovirus-mediated gene transfer for efficient target functionality validation, both in vivo and in vitro, with baculovirus expression to produce sufficient quantities of protein for high-throughput screening (HTS). The incorporation of green fluorescent protein (GFP) in the adenovirus vectors accelerates recombinant adenovirus plaque purification, whereas the use of epitope and affinity tags facilitates the identification and purification of recombinant protein. In this generalized scheme, the flexible modular design of viral vectors facilitates the transition between target validation and HTS. In the example presented, functional target validation in vivo was achieved by overexpressing the target gene in cell-based models and in the mouse cortex following adenovirus-mediated gene delivery. In this context, target overexpression resulted in the accumulation of a disease-related biomarker both in vitro and in vivo. A baculovirus-based expressional system was then generated to produce enough target protein for HTS. Thus, the use of these viral expression systems represents a generalized method for rapid target functionality validation and HTS assay development, which could be applied to numerous target candidates being elucidated in gene discovery programs.


Subject(s)
Adenoviridae , Genetic Vectors , Recombinant Proteins/analysis , Computational Biology
6.
Bioorg Med Chem ; 11(2): 185-92, 2003 Jan 17.
Article in English | MEDLINE | ID: mdl-12470712

ABSTRACT

The melanocortin-4 receptor (MC4) modulates physiological functions such as feeding behavior, nerve regeneration, and drug addiction. Using a high throughput screen based on (125)I-NDP-MSH binding to the human MC4 receptor, we discovered 2,3-diaryl-5-anilino[1,2,4]thiadiazoles 3 as potent and selective MC4 receptor agonists. Through SAR development on the three attached aryl rings, we improved the binding affinity from 174 nM to 4.4 nM IC(50). When delivered intraperitoneally, compounds 3a, 3b, and 3c induced significant inhibition of food intake in a fasting-induced feeding model in rats. When delivered orally, these compounds lost activity, mainly due to rapid metabolism to inactive imidoylthiourea reduction products.


Subject(s)
Feeding Behavior/drug effects , Receptors, Corticotropin/agonists , Thiadiazoles/chemical synthesis , Thiadiazoles/pharmacology , alpha-MSH/analogs & derivatives , Animals , Disease Models, Animal , Fasting/physiology , Feeding Behavior/physiology , Humans , Infusions, Parenteral , Inhibitory Concentration 50 , Iodine Radioisotopes , Male , Melanoma/metabolism , Rats , Rats, Long-Evans , Receptor, Melanocortin, Type 4 , Receptors, Corticotropin/metabolism , Structure-Activity Relationship , Tumor Cells, Cultured , alpha-MSH/metabolism
7.
J Pharmacol Exp Ther ; 303(2): 777-90, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12388665

ABSTRACT

5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5] imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide) (RWJ-51204) binds selectively and with high affinity (K(i) = 0.2-2 nM) to the benzodiazepine site on GABA(A) receptors. Considering the GABA shift, the intrinsic modulatory activity of RWJ-51204 is lower than that of full agonist anxiolytics (lorazepam, diazepam, alprazolam, and clonazepam) but similar to partial agonists (bretazenil, abecarnil, panadiplon, and imidazenil). RWJ-51204 was orally active in anxiolytic efficacy tests; pentylenetetrazole induced seizure inhibition in mice (ED(50) = 0.04 mg/kg), Vogel conflict in rats (ED(50) = 0.36 mg/kg), elevated plus-maze in rats (minimal effective dose = 0.1 mg/kg), and conflict in squirrel monkeys (ED(50) = 0.49 mg/kg). RWJ-51204 attenuated chlordiazepoxide-induced motor impairment in mice. Usually, RWJ-51204 was more potent than reference anxiolytics in rodent efficacy tests but less potent in monkey conflict. Usually, the slope of the dose-response lines for RWJ-51204 was more shallow than the full agonist anxiolytics but steeper than partial agonists in efficacy tests but typically shallow in tests for central nervous system side effects. In monkeys only mild or moderate sedation was observed at doses equivalent to 20 or 40 times the anxiolytic ED(50). RWJ-51204 fits into the partial agonist class of GABA(A) receptor modulators. In conclusion, RWJ-51204 exhibits a profile in in vitro experiments and in animal models, in mice and monkeys (but not in rats), suggesting that it has a profile of anxiolytic activity associated with less sedation, motor impairment, or muscle relaxation than currently available GABA(A) receptor modulators, i.e., the benzodiazepines.


Subject(s)
Anti-Anxiety Agents/pharmacology , Imidazoles/pharmacology , Pyridones/pharmacology , Animals , Behavior, Animal/drug effects , Central Nervous System Depressants/pharmacology , Chlordiazepoxide/pharmacology , Conflict, Psychological , Conscious Sedation , Convulsants , Drug Interactions , Ethanol/pharmacology , Flumazenil/pharmacology , GABA Modulators/pharmacology , Lorazepam/pharmacology , Male , Mice , Motor Activity/drug effects , Pentylenetetrazole , Postural Balance/drug effects , Rats , Rats, Long-Evans , Receptors, GABA-A/drug effects , Saimiri , Seizures/chemically induced , Seizures/prevention & control
8.
Bioorg Med Chem Lett ; 12(17): 2381-6, 2002 Sep 02.
Article in English | MEDLINE | ID: mdl-12161138

ABSTRACT

A series of pyrido[1,2-a]benzimidazoles (PBIs) with substitution on the N(5)-nitrogen has been synthesized and found to possess high affinity for the benzodiazepine (BZD) site on the GABA-A receptor. The compounds evaluated include those bearing a heteroalkyl group and heterocyclic rings. The most promising of these compounds is ethoxymethyl analogue 24, which has an IC(50) of 0.1 nM for the BZD site on the GABA-A receptor and has been advanced to human clinical trials.


Subject(s)
Anti-Anxiety Agents/chemical synthesis , GABA-A Receptor Agonists , Administration, Oral , Animals , Anti-Anxiety Agents/pharmacology , Benzimidazoles/chemical synthesis , Benzimidazoles/pharmacology , Cerebral Cortex/metabolism , Conflict, Psychological , Humans , Inhibitory Concentration 50 , Mice , Protein Binding , Pyridines/chemical synthesis , Pyridines/pharmacology , Rats , Seizures/chemically induced , Seizures/drug therapy , Sleep/drug effects , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...